The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system
- PDF / 684,222 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 15 Downloads / 203 Views
The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system Serdar Sahin1 · Tevhide Betul Icli2 · Emre Durcan1 · Cem Sulu1 · Hande Mefkure Ozkaya1 · Ali Ibrahim Hatemi3 · Pinar Kadioglu1 Accepted: 12 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly. Methods One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were evaluated. The upper gastrointestinal endoscopies and endoscopic biopsies were investigated. We divided patients into four groups according to the use of somatostatin analogs, and into two groups according to disease activity. We compared the data of patients between groups A, B, C, and D, and controlled/ uncontrolled groups separately. Results Before and in the peri-endoscopic period, 67 and 27 patients were being treated with octreotide long-acting release (LAR) (group A) and lanreotide autogel (group B), respectively. Twenty-one patients used somatostatin analogs, but they were stopped for various reasons before upper gastrointestinal endoscopy (group C), and 66 patients did not use a somatostatin analog (group D). In the peri-endoscopic period, 103 (60%) patients were responsive to medical and/or surgical treatment and 67 (40%) patients were non-responsive. The rate of gastritis was higher in group A than in groups B and D. The incidence of duodenitis and gastric ulcer was much higher in group D. The rate of gastritis was higher in the controlled group compared to the uncontrolled group. Conclusion The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly. Keywords Acromegaly · Upper gastrointestinal system · İntestinal metaplasia · Somatostatin analog · Gastritis
Introduction Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11102-020-01095-3) contains supplementary material, which is available to authorized users. * Pinar Kadioglu [email protected] 1
Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Street No: 53, Fatih, 34098 Istanbul, Turkey
2
Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
3
Division of Gastroenterology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
Acromegaly is a rare disease caused by excessive secretion of growth hormone (GH), usually due to a pituitary adenoma, and may affect multiple systems [1]. There are often several comorbidities at presentation in many patients with acromegaly because of delayed diagnosis [2]. The most common comorbidit
Data Loading...
